In vivo and in vitro treatment of HTLV-1 and HTLV-2 infected cells with arsenic trioxide and interferon-α

Leukemia and Lymphoma

Volumn 46, Issue 3, 2005, Pages 347-355

  Mahieux, Renaud ^a   Hermine, Olivier ^b  

^a INSTITUT PASTEUR   (France)

^b HÔPITAL NECKER ENFANTS MALADES   (France)

Author keywords

Alpha interferon; Arsenic trioxide; HTLV1; HTLV2; Infected cells

Indexed keywords

ALPHA INTERFERON; ANTINEOPLASTIC AGENT; ANTIVIRUS AGENT; ARSENIC TRIOXIDE; CD4 ANTIGEN; CELL DNA; COTRIMOXAZOLE; CYTOTOXIC AGENT; DNA TOPOISOMERASE INHIBITOR; GYRASE INHIBITOR; INTERLEUKIN 2 RECEPTOR; IRINOTECAN; MONOCLONAL ANTIBODY; NUCLEOSIDE ANALOG; PENTOSTATIN; SOBUZOXANE; VIRUS DNA; ZIDOVUDINE;

APOPTOSIS; CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CANCER REGRESSION; CARCINOGENESIS; CELL MATURATION; CELL TRANSFORMATION; CHRONIC DISEASE; CLINICAL FEATURE; CLINICAL TRIAL; CLONAL VARIATION; DISEASE SEVERITY; DRUG MECHANISM; DRUG POTENTIATION; DRUG USE; HUMAN; HUMAN T CELL LEUKEMIA VIRUS 1; HUMAN T CELL LEUKEMIA VIRUS 2; HUMAN T CELL LEUKEMIA VIRUS INFECTION; IN VITRO STUDY; IN VIVO STUDY; LATENT PERIOD; LEUKAPHERESIS; LYMPHOPROLIFERATIVE DISEASE; NONHUMAN; PATHOPHYSIOLOGY; PHOTOCHEMOTHERAPY; PRIORITY JOURNAL; PROVIRUS; REVIEW; SURVIVAL RATE; T CELL LEUKEMIA; T CELL LYMPHOMA; T LYMPHOCYTE ACTIVATION; TUMOR CELL; VIRUS DNA CELL DNA INTERACTION; WHOLE BODY RADIATION;

ANTI-RETROVIRAL AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; ARSENICALS; CELL PROLIFERATION; CLINICAL TRIALS, PHASE II; DRUG SYNERGISM; HUMAN T-LYMPHOTROPIC VIRUS 1; HUMAN T-LYMPHOTROPIC VIRUS 2; HUMANS; INTERFERON-ALPHA; LEUKEMIA-LYMPHOMA, T-CELL, ACUTE, HTLV-I-ASSOCIATED; NF-KAPPA B; OXIDES; TUMOR VIRUS INFECTIONS;

EID: 13544267787     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.1080/10428190400019966     Document Type: Review

References (71)

1. Johnson JM, Harrod R, Franchini G. Molecular biology and pathogenesis of the human T-cell leukaemia/lymphotropic virus Type-1 (HTLV-1). Int J Exp Pathol 2001;82:135-147.
2. Mesnard JM, Devaux C. Multiple control levels of cell proliferation by human T-cell leukemia virus type 1 Tax protein. Virology 1999;257:277-284.
3. Hanon E, Hall S, Taylor GP, Saito M, Davis R, Tanaka Y, Usuku K, Osame M, Weber JN, Bangham CR. Abundant tax protein expression in CD4+ T cells infected with human T-cell lymphotropic virus type I (HTLV-I) is prevented by cytotoxic T lymphocytes. Blood 2000;95:1386-1392.
4. Manel N, Kim FJ, Kinet S, Taylor N, Sitbon M, Battini JL. The ubiquitous glucose transporter GLUT-1 is a receptor for HTLV. Cell 2003;115:449-459.
5. Inoue J, Itoh M, Akizawa T, Toyoshima H, Yoshida M. HTLV-1 Rex protein accumulates unspliced RNA in the nucleus as well as in cytoplasm. Oncogene 1991;6:1753-1757.
6. Meertens L, Chevalier S, Weil R, Gessain A, Mahieux R. A 10-Amino Acid Domain within Human T-cell Leukemia Virus Type 1 and Type 2 Tax Protein Sequences Is Responsible for Their Divergent Subcellular Distribution. J Biol Chem 2004;279:43307-43320.
7. Jeang KT, Giam CZ, Majone F, Aboud M. Life, death, and tax: role of HTLV-I oncoprotein in genetic instability and cellular transformation. J Biol Chem 2004;279:31991-31994.
8. Grassmann R, Fleckenstein B, Desrosiers RC. Viral transformation of human T lymphocytes. Adv Cancer Res 1994;63:211-244.
9. Pozzatti R, Vogel J, Jay G. The human T-lymphotropic virus type I tax gene can cooperate with the ras oncogene to induce neoplastic transformation of cells. Mol Cell Biol 1990;10:413-417.
10. Liang MH, Geisbert T, Yao Y, Hinrichs SH, Giam CZ. Human T-lymphotropic virus type 1 oncoprotein tax promotes S-phase entry but blocks mitosis. J Virol 2002;76:4022-4033.
11. Grossman WJ, Kimata JT, Wong FH, Zutter M, Ley TJ Ratner L. Development of leukemia in mice transgenic for the tax gene of human T-cell leukemia virus type I. Proc Natl Acad Sci USA 1995;92:1057-1061.
12. Yin MJ, Gaynor RB. Complex formation between CREB and Tax enhances the binding affinity of CREB for the human T-cell leukemia virus type 1 21-base-pair repeats. Mol Cell Biol 1996;16:3156-3168.
13. Jiang H, Lu H, Schiltz RL, Pise-Masison CA, Ogryzko VV, Nakatani Y, Brady JN. PCAF interacts with tax and stimulates tax transactivation in a histone acetyltransferase-independent manner. Mol Cell Biol 1999;19:8136-8145.
14. Harrod R, Tang Y, Nicot C, Lu HS, Vassilev A, Nakatani Y, Giam CZ. An exposed KID-like domain in human T-cell lymphotropic virus type 1 Tax is responsible for the recruitment of coactivators CBP/p300. Mol Cell Biol 1999;18:5052-5061.
15. Koga H, Ohshima T, Shimotohno K. Enhanced activation of tax dependent transcription of HTLV-I LTR by TORC3. J Biol Chem. 2004; in press.
16. Sun SC, Harhaj EW, Xiao G, Good L. Activation of I-kappaB kinase by the HTLV type 1 Tax protein: mechanistic insights into the adaptor function of IKKgamma. AIDS Res Hum Retroviruses 2000;16:1591-1596.
17. Pise-Masison CA, Mahieux R, Radonovich M, Jiang H, Duvall J, Guillerm C, Brady JN. Insights into the molecular mechanism of p53 inhibition by HTLV type 1 Tax (In Process Citation). AIDS Res Hum Retroviruses 2000;16:1669-1675.
18. Yoshida M, Suzuki T. HTLV type 1 tax oncoprotein binds to DNA topoisomerase I and inhibits its catalytic activity (In Process Citation). AIDS Res Hum Retroviruses 2000;16:1639-1645.
19. Arnulf B, Villemain A, Nicot C, Mordelet E, Charneau P, Kersual J, Zermati Y, Mauviel A, Bazarbachi A, Hermine O. Human T-cell lymphotropic virus oncoprotein Tax represses TGF-beta 1 signaling in human T cells via c-Jun activation: a potential mechanism of HTLV-I leukemogenesis. Blood 2002;100:4129-4138.
20. Matsuoka M. Human T-cell leukemia virus type I and adult T-cell leukemia. Oncogene 2003;22:5131-5140.
21. Gatza ML, Watt JC, Marriott SJ. Cellular transformation by the HTLV-I Tax protein, a jack-of-all-trades. Oncogene 2003;22:5141-5149.
22. Jeang KT, Widen SG, Semmes OJT, Wilson SH. HTLV-I trans-activator protein, tax, is a trans-repressor of the human beta-polymerase gene. Science 1990;247:1082-1084.
23. Suzuki T, Uchida-Toita M, Andoh T, Yoshida M. HTLV-1 tax oncoprotein binds to DNA topoisomerase I and inhibits its catalytic activity. Virology 2000;270:291-298.
24. Sinha-Datta U, Horikawa I, Michishita E, Datta A, Sigler-Nicot J, Brown M, Kazanji M, Barrett J, Nicot C. Transcriptional activation of hTERT in HTLV-1 transformed cells through the NF-kB pathway. Blood 2004;104:2523-2531.
25. Gabet AS, Mortreux F, Charneau P, Riou P, Duc-Dodon M, Wu Y, Jeang KT, Wattel E. Inactivation of hTERT transcription by Tax. Oncogene 2003;22:3734-3741.
26. Yamaguchi K, Nishimura H, Kohrogi H, Jono M, Miyamoto Y, Takatsuki K. A proposal for smoldering adult T-cell leukemia: a clinicopathologic study of five cases. Blood 1983;62:758-766.
27. Yamaguchi K, Watanabe T. Human T lymphotropic virus type-I and adult T-cell leukemia in Japan. Int J Hematol 2002;76 Suppl 2:S240-S245.
28. Yoshida M, Seiki M, Yamaguchi K, Takatsuki K. Monoclonal integration of human T-cell leukemia provirus in all primary tumors of adult T-cell leukemia suggests causative role of human T-cell leukemia virus in the disease. Proc Natl Acad Sci USA 1984;81:2534-2537.
29. Asquith B, Hanon E, Taylor GP, Bangham CR. Is human T-cell lymphotropic virus type I really silent? Philos Trans R Soc Lond B Biol Sci 2000;355:1013-1019.
30. Arnulf B, Thorel M, Poirot Y, Tamouza R, Boulanger E, Jaccard A, Oksenhendler E, Hermine O, Pique C. Loss of the ex vivo but not the reinducible CD8+ T-cell response to Tax in human T-cell leukemia virus type 1-infected patients with adult T-cell leukemia/lymphoma. Leukemia 2004;18:126-132.
31. Kalyanaraman VS, Sarngadharan MG, Robert-Guroff M, Miyoshi I, Golde D, Gallo RC. A new subtype of human T-cell leukemia virus (HTLV-II) associated with a T-cell variant of hairy cell leukemia. Science 1982;218:571-573.
32. Fouchard N, Flageul B, Bagot M, Avril MF, Hermine O, Sigaux F, Merle-Beral H, Troussard X, Delfraissy JF, de The G, et al. Lack of evidence of HTLV-I/II infection in T CD8 malignant or reactive lymphoproliferative disorders in France: a serological and/or molecular study of 169 cases. Leukemia 1995;9:2087-2092.
33. Yamaguchi K, Seiki M, Yoshida M, Nishimura H, Kawano F, Takatsuki K. The detection of human T cell leukemia virus proviral DNA and its application for classification and diagnosis of T cell malignancy. Blood 1984;63:1235-1240.
34. Tajima K. The 4th nation-wide study of adult T-cell leukemia/lymphoma (ATL) in Japan: estimates of risk of ATL and its geographical and clinical features. The T- and B-cell Malignancy Study Group. Int J Cancer 1990;45:237-243.
35. Anonymous. The third nation-wide study on adult T-cell leukemia/lymphoma (ATL) in Japan: characteristic patterns of HLA antigen and HTLV-I infection in ATL patients and their relatives. The T- and B-cell Malignancy Study Group. Int J Cancer 1988;41:505-512.
36. Arisawa K, Soda M, Endo S, Kurokawa K, Katamine S, Shimokawa I, Koba T, Takahashi T, Saito H, Doi H, Shirahama S. Evaluation of adult T-cell leukemia/lymphoma incidence and its impact on non-Hodgkin lymphoma incidence in southwestern Japan. Int J Cancer 2000;85:319-324.
37. Hermine O, Wattel E, Gessain A, Bazarbachi A. Adult T Cell Leukemia, a review of established and new treatments. BioDrugs 1998;10:447-462.
38. Shirono K, Hattori T, Hata H, Nishimura H, Takatsuki K. Profiles of expression of activated cell antigens on peripheral blood and lymph node cells from different clinical stages of adult T-cell leukemia. Blood 1989;73:1664-1671.
39. Takatsuki K, Yamaguchi K, Matsuoka M. Adult T-cell leukemia. In: Holsberg HDP, editor. Human T Cell Lymphotropic Virus Type 1. New York: Wiley; 1996. pp 219-246.
40. Uchiyama T, Ishikawa T, Kondo A. In: Takatsuki T, editor. Adult T-cell Leukemia. Pathophysiology of ATL cells: cell growth characteristics Oxford: Oxford University Press; 1994. pp 181-203.
41. Hermine O, Arnulf B, Bazarbachi A. Treatment of adult-T cell leukemia/lymphoma: clinical results of new therapeutic approaches. AIDS Res Hum retroviruses 2001;17:S29.
42. Siegel RS, Gartenhaus RB, Kuzel TM. Human T-cell lymphotropic-I-associated leukemia/lymphoma. Curr Treat Options Oncol 2001;2:291-300.
43. Yamada Y, Tomonaga M, Fukuda H, Hanada S, Utsunomiya A, Tara M, Sano M, Ikeda S, Takatsuki K, Kozuru M, et al. A new G-CSF-supported combination chemotherapy, LSG15, for adult T-cell leukaemia-lymphoma: Japan Clinical Oncology Group Study 9303. Br J Haematol 2001;113:375-382.
44. Bazarbachi A, Ghez D, Lepelletier Y, Nasr R, de The ME, El Sabbon ME, Hermine O. Novel therapeutic approaches for adult T cell leukemia. Lancet Oncol 2004;5:664-672.
45. Zhang J, Balestrieri E, Grelli S, Matteucci C, Pagnini V, D'Agostini C, Mastino A, Macchi B. Efficacy of 3′-azido 3′deoxythymidine (AZT) in preventing HTLV-1 transmission to human cord blood mononuclear cells. Virus Res 2001;78:67-78.
46. Gill PS, Harrington W Jr, Kaplan MH, Ribeiro RC, Bennett JM, Liebman HA, Bernstein-Singer M, Espina BM, Cabral L, Allen S, et al. Treatment of adult T-cell leukemia-lymphoma with a combination of interferon alfa and zidovudine. N Engl J Med 1995;332:1744-1748.
47. Hermine O, Bouscary D, Gessain A, Turlure P, Leblond V, Franck N, Buzyn-Veil A, Rio B, Macintyre E, Dreyfus F, et al. Brief report: treatment of adult T-cell leukemia-lymphoma with zidovudine and interferon alfa. N Engl J Med 1995;332:1749-1751.
48. Bazarbachi A, Hermine O. Treatment with a combination of zidovudine and alpha-interferon in naive and pretreated adult T-cell leukemia/lymphoma patients. J Acquir Immune Defic Syndr Hum Retrovirol 1996;13 Suppl 1:S186-190.
49. Matutes E, Taylor GP, Cavenagh J, Pagliuca A, Bareford D, Domingo A, Hamblin M, Kelsey S, Mir N, Reilly JT. Interferon alpha and zidovudine therapy in adult T-cell leukaemia lymphoma: response and outcome in 15 patients. Br J Haematol 2001;113:779-784.
50. Soignet SL, Frankel Sr, Douer D, Tallman MS, Kantarjian H, Calleja E, Stone RM, Kalaycio M, Scheinberg DA, Steinherz P, et al. United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia. J Clin Oncol 2001;19, 3852-3860.
51. Shen ZX, Chen GQ, Ni JH, Li XS, Xiong SM, Qiu QY, Zhu J, Tang W, Sun GL, Yang KQ, et al. Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood 1997;89:3354-3360.
52. Chen GQ, Shi XG, Tang W, Xiong SM, Zhu J, Cai X, Han ZG, Ni JH, Shi GY, Jia PM, et al. Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): I. As2O3 exerts dose-dependent dual effects on APL cells. Blood 1997;89:3345-3353.
53. Chen GQ, Zhu J, Shi XG, Ni JH, Zhong HJ, Si GY, Jin XL, Tang W, Li XS, Xong, SM, et al. In vitro studies on cellular and molecular mechanisms of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia: As2O3 induces NB4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML-RAR alpha/PML proteins. Blood 1996;88:1052-1061.
54. Zhu J, Chen Z, Lallemand-Breitenbach V, de The H. How acute promyelocytic leukaemia revived arsenic. Nat Rev Cancer 2002;2:705-713.
55. Lu M, Levin J, Sulpice E, Sequeira-Le Grand A, Alemany M, Caen JP, Han ZC. Effect of arsenic trioxide on viability, proliferation, and apoptosis in human megakaryocytic leukemia cell lines. Exp Hematol 1999;27:845-852.
56. Zheng J, Deng YP, Lin C, Fu M, Xiao PG, Wu M. Arsenic trioxide induces apoptosis of HPV16 DNA-immortalized human cervical epithelial cells and selectively inhibits viral gene expression. Int J Cancer 1999;82:286-292.
57. Shen ZY, Tan LJ, Cai WJ, Shen J, Chen C, Tang XM, Zheng MH. Arsenic trioxide induces apoptosis of oesophageal carcinoma in vitro. Int J Mol Med 1999;4:33-37.
58. Rousselot P, Labaume S, Marolleau JP, Larghero J, Noguera MH, Brouet JC, Fermand JP. Arsenic trioxide and melarsoprol induce apoptosis in plasma cell lines and in plasma cells from myeloma patients. Cancer Res 1999;59:1041-1048.
59. Akay C, Thomas C 3rd, Gazitt Y. Arsenic Trioxide and Paclitaxel Induce Apoptosis by Different Mechanisms. Cell Cycle 2004;3:324-334.
60. Rojewski MT, Korper S, Thiel E, Schrezenmeier H. Arsenic trioxide-induced apoptosis is independent of CD95 in lymphatic cell lines. Oncol Rep 2004;11:509-513.
61. Chen YC, Lin-Shiau SY, Lin JK. Involvement of reactive oxygen species and caspase 3 activation in arsenite-induced apoptosis. J Cell Physiol 1998;177:324-333.
62. Adachi S, Leoni LM, Carson DA, Nakahata T. Apoptosis induced by molecular targeting therapy in hematological malignancies. Acta Haematol 2004;111:107-123.
63. Ishitsuka K, Hanada S, Suzuki S, Utsunomiya A, Chyuman Y, Takeuchi S, Takeshita T, Shimotakahara S, Uozumi K, Makino T, Arima T. Arsenic trioxide inhibits growth of human T-cell leukaemia virus type I infected T-cell lines more effectively than retinoic acids. Br J Haematol 1998;103:721-728.
64. Darwiche N, El-Sabban M, Bazzi R, Nasr R, Al-Hashimi S, Hermine O, de The H, Bazarbachi A. Retinoic acid dramatically enhances the arsenic trioxide-induced cell cycle arrest and apoptosis in retinoic acid receptor alpha-positive human T-cell lymphotropic virus type-I-transformed cells. Hematol J 2001;2:127-135.
65. Bazarbachi A, El-Sabban ME, Nasr R, Quignon F, Awaraji C, Kersual J, Dianoux L, Zermati Y, Haidar JH, Hermine O, de The H. Arsenic trioxide and interferon-alpha synergize to induce cell cycle arrest and apoptosis in human T-cell lymphotropic: virus type I-transformed cells. Blood 1999;93:278-283.
66. Ishitsuka K, Hanada S, Uozumi K, Utsunomiya A Arima T. Arsenic trioxide and the growth of human t-cell leukemia virus type i infected t-cell lines. Leuk Lymphoma 2000;37:649-655.
67. El-Sabban ME, Nasr R, Dbaibo G, Hermine O, Abboushi N, Quignon F, Ameisen JC, Bex F, de The H, Bazarbachi A. Arsenic-interferon-alpha-triggered apoptosis in HTLV-I transformed cells is associated with tax down-regulation and reversal of NF-kappaB activation. Blood 2000;96:2849-2855.
68. Mahieux R, Pise-Masison C, Gessain A, Brady JN, Olivier R, Perret E, Misteli T, Nicot C. Arsenic trioxide induces apoptosis in human T-cell leukemia virus type 1- and type 2-infected cells by a caspase-3-dependent mechanism involving Bcl-2 cleavage. Blood 2001;98:3762-3769.
69. Ishitsuka K, Ikeda R, Utsunomiya A, Uozumi K, Hanada S, Suzuki S, Takeuchi S, Takatsuka Y, Takeshita T, Ohno N, Arima T. Arsenic trioxide induces apoptosis in HTLV-I infected T-cell lines and fresh adult T-cell leukemia cells through CD95 or tumor necrosis factor alpha receptor independent caspase activation. Leuk Lymphoma 2002;43:1107-1114.
70. Nasr R, Rosenwald A, El-Sabban ME, Arnulf B, Zalloua P, Lepelletier Y, Bex F, Hermine O, Staudt L, de The H, Bazarbachi A. Arsenic/interferon specifically reverses 2 distinct gene networks critical for the survival of HTLV-1-infected leukemic cells. Blood 2003;101:4576-4582.
71. Hermine O, Dombret H, Poupon J, Arnulf B, Lefrere F, Rousselot P, Damaj G, Delarue R, Fermand JP, Brouet JC, et al. Phase II trial of arsenic trioxide and alpha interferon in patients with relapsed/refractory adult T-cell leukemia/ lymphoma. Hematol J 2004;5:130-134.